(redirected from Claritin reditabs)
Also found in: Dictionary.


a nonsedating antihistamine (H1 receptor antagonist) used for treatment of allergic rhinitis and chronic idiopathic urticaria and as a treatment adjunct in asthma; administered orally.


Aerius (CA), Alavert, Allertin, Claritin, Claritin RediTabs, Clarityn (UK)

Pharmacologic class: Histamine1-receptor antagonist (second-generation)

Therapeutic class: Antihistamine (nonsedating)

Pregnancy risk category B


Selective histamine1-receptor antagonist. Blocks peripheral effects of histamine release during allergic reactions, decreasing or preventing allergy symptoms.


Syrup: 1 mg/ml

Tablets: 10 mg

Tablets (rapidly disintegrating): 10 mg

Indications and dosages

Seasonal allergies; chronic idiopathic urticaria

Adults and children ages 6 and older: 10 mg P.O. daily

Children ages 2 to 5: 5 mg P.O. daily

Dosage adjustment

• Renal or hepatic impairment


• Hypersensitivity to drug


Use cautiously in:
• renal or hepatic impairment
• elderly patients
• pregnant patients
• children younger than age 2 (safety not established).


• Give once a day on empty stomach.
• Place rapidly disintegrating tablet on tongue; give with or without water.
• Use rapidly disintegrating tablets within 6 months of opening foil pouch and immediately after opening individual tablet blister.

Adverse reactions

CNS: headache, nervousness, insomnia

EENT: conjunctivitis, earache, epistaxis, pharyngitis

GI: abdominal pain; dry mouth; diarrhea, stomatitis (in children)

Skin: rash, photosensitivity, angioedema

Other: tooth disorder (in children), fever, flulike symptoms, viral infections


Drug-food.Any food: increased drug absorption

Patient monitoring

• Watch for adverse reactions, especially in children.
• Assess patient's response to drug.
• Watch for new symptoms or exacerbation of existing symptoms.

Patient teaching

• Advise patient to take exactly as prescribed, once a day on empty stomach.
• Tell patient to report persistent or worsening symptoms.
• Instruct patient to report adverse reactions, such as headache or nervousness.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the foods mentioned above.


/lor·at·a·dine/ (lah-rat´ah-dēn) a nonsedating antihistamine used in the treatment of allergic rhinitis, chronic idiopathic urticaria, and asthma.


A nonsedating antihistamine, C22H23ClN2O2, used to treat allergic rhinitis and other allergic disorders.


a nonsedating antihistamine (H1-receptor antagonist) used for treatment of allergic rhinitis and chronic idiopathic urticaria and as a treatment adjunct in asthma, administered orally.


An ANTIHISTAMINE drug used to treat hay fever and other allergic disorders.


Any substance that reduces the effect of histamine or blocks histamine receptors, usually the histamine 1 (H1) receptor. It is used in the treatment of allergic conjunctivitis and also in the temporary relief of minor allergic symptoms of the eye. Common agents include antazoline sulfate, azelastine hydrochloride, cetirizine, chlorphenamine, emedastine, epinastine hydrochloride, ketotifen, levocabastine, loratadine and olopatadine. See hypersensitivity; mast cell stabilizers.


n brand name: Claritin;
drug class: antihistamine, H1 histamine antagonist;
action: acts on blood vessels, gastrointestinal system, respiratory system by competing with histamine for H1-receptor site; decreases allergic response by blocking histamine;
uses: seasonal rhinitis, allergy symptoms, idiopathic chronic urticaria.
References in periodicals archive ?
In addition to CLARITIN RediTabs, there are currently five prescription products which utilize the Zydis technology being marketed around the world.
The FDA granted final marketing approval for Claritin-D 24 in February 2003, and to the Company's knowledge, the only substantive matter delaying approval of Andrx's bioequivalent versions of Claritin D-12 and Claritin Reditabs is the expiration of the 180-day market exclusivity period for each of those products.
A recently conducted survey of 800 allergy sufferers in Japan found more than 60 percent of patients prefer to take CLARITIN RediTabs.
Claritin RediTabs is a quickly-dissolving tablet antihistamine for the relief of symptoms due to hay fever or other upper respiratory allergies.
Claritin-D 12 Hour, Claritin RediTabs and Claritin-D 24 Hour are registered trademarks of Schering-Plough Corporation.
Schering markets Claritin Reditabs for the relief of symptoms of seasonal allergic rhinitis (hayfever).
IMPAX has made this application under Paragraph IV of the Hatch-Waxman Amendments stating the Company's belief that its product does not infringe Schering-Plough Corporation's listed patents on Claritin Reditabs.
The Andrx ANDA for a bioequivalent version of Claritin Reditabs remains the subject of patent infringement litigation initiated by Schering-Plough.
This press release, including the information related to a generic fast-dissolve version of Claritin RediTabs, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Schering Plough Corporation (NYSE:SGP) markets Claritin Reditabs as an over-the-counter (OTC) drug for the relief of symptoms of seasonal allergic rhinitis (hay fever).
All Claritin brand products are available without a prescription, including: Claritin Tablets, a once-daily full prescription strength, non-drowsy formulation; Claritin RediTabs Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; Claritin-D 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine Now Located Behind The Counter; Children's Claritin Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; CHILDREN'S Claritin Grape Chewables, a chewable tablet for children ages 2 and older; and Claritin Hives Relief tablets.